Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 139

Sort by

Sort Order Select

Journal Articles

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Blood (2025) 146 (Supplement 1): 669.

https://doi.org/10.1182/blood-2025-669

Published: 2025

Journal Articles

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Blood (2025) 146 (Supplement 1): 467.

https://doi.org/10.1182/blood-2025-467

Published: 2025

Journal Articles

Real world use of sutimlimab in patients with cold agglutinin disease: An international study

Blood (2025) 146 (Supplement 1): 1100.

https://doi.org/10.1182/blood-2025-1100

Published: 2025

Journal Articles

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Blood (2025) 146 (Supplement 1): 811.

https://doi.org/10.1182/blood-2025-811

Published: 2025

Journal Articles

Real-world safety of sutimlimab in patients with CAD/CAS: A multinational, multi-center, observational, prospective cohort Study

Alexander Röth, Marc Michel, Wilma Barcellini, Ulrich Jaeger, Yasutaka Ueda, Quentin A. Hill, Joan Cid, Kelley Dacus, Mounia Beloueche, Catherine Broome

Blood (2025) 146 (Supplement 1): 6242.

https://doi.org/10.1182/blood-2025-6242

Published: 2025

Journal Articles

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

Blood (2025) 145 (23): 2733–2745.

https://doi.org/10.1182/blood.2024025525

Published: 2025

Includes: Supplemental data

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Blood (2024) 144 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2024-198509

Published: 2024

Journal Articles

Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update

Blood (2024) 144 (Supplement 1): 67.

https://doi.org/10.1182/blood-2024-204264

Published: 2024

Journal Articles

First Interim Analysis of Patients with Cold Agglutinin Disease (CAD) Patients and the Sutimlimab-Treated Subgroup from the Cadence Registry

Catherine M. Broome, Marc Michel, Wilma Barcellini, Ulrich Jaeger, Yasutaka Ueda, Quentin A. Hill, Joan Cid, Jiangming Wu, Shruti Srivastava, Marek Wardęcki, Reena Patel, Ronnie Yoo, Alexander Röth

Blood (2024) 144 (Supplement 1): 7667.

https://doi.org/10.1182/blood-2024-206942

Published: 2024

Journal Articles

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 602.

https://doi.org/10.1182/blood-2023-179474

Published: 2023

Journal Articles

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

Blood (2023) 142 (Supplement 1): 435.

https://doi.org/10.1182/blood-2023-172951

Published: 2023

Journal Articles

Cold Agglutinin Disease (CAD) Real-World Evidence (CADENCE) Registry: Update to the Study Design of the First International, Prospective CAD Registry

Alexander Roeth, Wilma Barcellini, Ulrich Jaeger, Yasutaka Ueda, Marc Michel, Quentin A. Hill, Shruti Srivastava, Ronnie Yoo, Catherine M. Broome

Blood (2023) 142 (Supplement 1): 7341.

https://doi.org/10.1182/blood-2023-180678

Published: 2023

Journal Articles

Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells

Rakesh Awasthi, Edward Waldron, Stephan Grupp, Michael A. Pulsipher, Peter Bader, Stephen J Schuster, Richard T Maziarz, Edmund K. Waller, Ulrich Jaeger, Catherine Thieblemont, Martin Dreyling, Nathan Fowler, Harald Jakob Maier, Jennifer Willert

Blood (2023) 142 (Supplement 1): 4872.

https://doi.org/10.1182/blood-2023-181663

Published: 2023

Journal Articles

Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial

Lukas Kazianka, Tea Pemovska, Johannes Rohrbeck, Christoph Kornauth, Alexander Pichler, Christiane Agreiter, Simone Lubowitzki, Katharina Prochazka, Peter Neumeister, Clemens Schmitt, Richard Greil, Wolfgang Willenbacher, Dominik Wolf, Ulrich Jaeger, Ingrid Simonitsch-Klupp, Philipp Bernhard Staber

Blood (2023) 142 (Supplement 1): 5006.

https://doi.org/10.1182/blood-2023-189856

Published: 2023

Journal Articles

Distinct Subtypes of Chemotherapy-Resistant Systemic ALK-Positive Anaplastic Large Cell Lymphoma Demonstrate Long-Term Complete Remissions to Imatinib

Alexander Pichler, Christoph Kornauth, Ines Garces De Los Fayos Alonso, Lukas Kazianka, Arne Zibat, Luca Mologni, Halima Alachram, Tea Pemovska, Gerwin Heller, Richard Greil, Lukas Kenner, Ulrich Jaeger, Philipp Bernhard Staber

Blood (2023) 142 (Supplement 1): 1691.

https://doi.org/10.1182/blood-2023-188835

Published: 2023

Journal Articles

Delineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies

Irene Graf, Georg Greiner, Karoline V. Gleixner, Susanne Herndlhofer, Gabriele Stefanzl, Paul Knöbl, Alexander Hauswirth, Manja Meggendorfer, Ulrich Jaeger, Constance Baer, Torsten Haferlach, Gregor Hoermann, Peter Valent, Wolfgang R. Sperr

Blood (2022) 140 (Supplement 1): 11634–11635.

https://doi.org/10.1182/blood-2022-162588

Published: 2022

Journal Articles

Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia

Arnon P. Kater, Barbara Eichhorst, Carolyn Owen, Ulrich Jaeger, Brenda Chyla, Marcus Lefebure, Rosemary Millen, Yanwen Jiang, Maria Thadani-Mulero, John F. Seymour

Blood (2022) 140 (Supplement 1): 7010–7012.

https://doi.org/10.1182/blood-2022-158275

Published: 2022

Journal Articles

YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update

Blood (2022) 140 (Supplement 1): 1056–1059.

https://doi.org/10.1182/blood-2022-162520

Published: 2022

Journal Articles

Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network

Jakob D. Rudzki, Ulrich Jaeger, Dominik Wolf, Andreas Petzer, Richard Greil, Christina Peters, Hildegard T. Greinix, Andishe Attarbaschi, Veronika Buxhofer-Ausch, Michael Girschikofsky, Wolfgang Holter, Michael Leisch, Peter Neumeister, Peter Schlenke, Clemens A. Schmitt, Wolfgang Schwinger, Nina Worel, Philipp Wohlfarth

Blood (2022) 140 (Supplement 1): 6661–6663.

https://doi.org/10.1182/blood-2022-167603

Published: 2022

Journal Articles

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Peter Borchmann, Peter Vandenberghe, Alvaro Urbano-Ispizua, Corinne Haioun, Francois Lemonnier, Laimonas Griskevicius, Sébastien Maury, Silke Holtkamp, Birte Friedrichs, Gregor Zadoyan, Linda Hanssens, Toon Overstijns, Mario Assenmacher, Ulf Bethke, Iris Bürger, Olaf Reer, Ulrich Jaeger, Marie José Kersten

Blood (2022) 140 (Supplement 1): 12784–12785.

https://doi.org/10.1182/blood-2022-164650

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Real world use of sutimlimab in patients with cold agglutinin disease: An international study

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Real-world safety of sutimlimab in patients with CAD/CAS: A multinational, multi-center, observational, prospective cohort Study

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update

First Interim Analysis of Patients with Cold Agglutinin Disease (CAD) Patients and the Sutimlimab-Treated Subgroup from the Cadence Registry

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

Cold Agglutinin Disease (CAD) Real-World Evidence (CADENCE) Registry: Update to the Study Design of the First International, Prospective CAD Registry

Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells

Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial

Distinct Subtypes of Chemotherapy-Resistant Systemic ALK-Positive Anaplastic Large Cell Lymphoma Demonstrate Long-Term Complete Remissions to Imatinib

Delineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies

Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia

YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update

Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only